Use of kinase inhibitors to manage tuberculosis and other infectious diseases
This disclosure relates to the use of kinase inhibitor to treat or prevent infectious diseases such as tuberculosis. In certain embodiments, this disclosure relates to treating or preventing an infectious disease comprising administering an effective amount of a kinase inhibitor or other compound disclosed herein to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing tuberculosis comprising administering a kinase inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with Mycobacterium tuberculosis (Mtb) that is resistant to multiple antibiotic agents.
1. A method of treating tuberculosis comprising administering imatinib in an amount of 50 to 400 mg per day in combination with another antibiotic selected from ethambutol, isoniazid, pyrazinamide, rifabutin, rifampin, rifapentine, amikacin, capreomycin, cycloserine, ethionamide, levofloxacin, moxifloxacin, para-aminosalicylic acid, streptomycin, or combinations thereof, to a human subject in need thereof.
2. The method of claim 1 , wherein imatinib is administered in the amount of 50 to 100 mg per day.
3. The method of claim 1 , wherein the subject is diagnosed with or exhibiting symptoms of an active tuberculosis infection.
4. A pharmaceutical product comprising a combination of imatinib and an antiviral agent.
5. The pharmaceutical product of claim 4 , wherein the antiviral agent is a combination selected from:
a combination of abacavir and lamivudine;
a combination of abacavir, dolutegravir, and lamivudine;
a combination of abacavir, lamivudine, and zidovudine;
a combination of atazanavir and cobicistat;
a combination of darunavir and cobicistat;
a combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate;
a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide fumarate;
a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate;
a combination of emtricitabine, rilpivirine, and tenofovir alafenamide;
a combination of emtricitabine, rilpivirine, and tenofovir disoproxil fumarate;
a combination of emtricitabine and tenofovir alafenamide;
a combination of emtricitabine and tenofovir disoproxil fumarate;
a combination of lamivudine and zidovudine; and
a combination of lopinavir and ritonavir.
6. The pharmaceutical product of claim 4 , wherein the antiviral agent is a nucleoside reverse transcriptase inhibitor (NRTI) selected from abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, and zidovudine, or combinations thereof.
7. The pharmaceutical product of claim 4 , wherein the antiviral agent is a non-nucleoside reverse transcriptase inhibitor (NNRTI) selected from efavirenz, etravirine, nevirapine, and rilpivirine, or combinations thereof.
8. The pharmaceutical product of claim 4 , wherein the antiviral agent is a protease inhibitor selected from atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, and tipranavir, or combinations thereof.
9. A method of treating or preventing tuberculosis comprising administering imatinib to a human subject in need thereof diagnosed with HIV.
10. The method of claim 9 wherein imatinib is administered in combination with an antiviral agent.
11. The method of claim 10 wherein the antiviral agent is a combination selected from:
a combination of abacavir and lamivudine;
a combination of abacavir, dolutegravir, and lamivudine;
a combination of abacavir, lamivudine, and zidovudine;
a combination of atazanavir and cobicistat;
a combination of darunavir and cobicistat;
a combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate;
a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide fumarate;
a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate;
a combination of emtricitabine, rilpivirine, and tenofovir alafenamide;
a combination of emtricitabine, rilpivirine, and tenofovir disoproxil fumarate;
a combination of emtricitabine and tenofovir alafenamide;
a combination of emtricitabine and tenofovir disoproxil fumarate;
a combination of lamivudine and zidovudine; and
a combination of lopinavir and ritonavir.
12. The method of claim 9 , wherein imatinib is administered in the amount of 50 to 400 mg per day.
13. The method of claim 9 , wherein imatinib is administered in the amount of 50 to 100 mg per day.
14. A method of preventing reactivation of a latent tuberculosis infection comprising administering imatinib in an amount of 50 to 400 mg per day to a human subject in need thereof, wherein administration prevents reactivation of a latent tuberculosis infection.
15. A method of treating tuberculosis comprising administering imatinib in an amount of 50 to 400 mg per day to a human subject in need thereof, wherein the subject is resistant to treatment of tuberculosis with rifampicin.
16. The method of claim 15 , wherein imatinib is administered in the amount of 50 to 100 mg per day.
17. The method of claim 15 , wherein the subject is diagnosed with or exhibiting symptoms of an active tuberculosis infection.
18. A method of treating tuberculosis comprising administering imatinib in an amount of 50 to 400 mg per day in combination with bedaquiline to a human subject in need thereof.
19. A method of treating tuberculosis comprising administering imatinib in an amount of 50 to 400 mg per day in combination with delamanid to a human subject in need thereof.